Regulatory Challenges In The Development And Approval Of Herbal Medicines

Figure 1. Key regulatory challenges

3. MAJOR REGULATORY CHALLENGES

Botanical authentication is fundamental because substitution or misidentification can alter safety and efficacy. Variability is influenced by species, chemotype, plant part, geography, cultivation, harvesting, drying, extraction and storage. GACP, pharmacopoeial standards and documented supply-chain controls are therefore important. [13–18]

Standardization remains difficult because many herbal products contain numerous constituents and no single compound necessarily explains the therapeutic effect. A combination of chromatographic fingerprints, marker compounds, spectroscopic methods, DNA authentication and chemometric approaches can improve characterization. [19–24]

Contamination and adulteration are major safety concerns. Pesticide residues, heavy metals, microbes, mycotoxins, residual solvents and undeclared pharmaceutical substances may occur. Risk-based specifications, validated analytical methods and appropriate supplier qualification are necessary. [25–30]

Evidence requirements are another major challenge. Traditional use can provide supportive evidence but may not establish modern standards of efficacy, dose-response or safety. Regulatory pathways differ between traditional-use products and products developed as medicines through conventional clinical development. [31–35]

Manufacturing and lifecycle management require special attention because changes in raw materials, extraction processes or suppliers can modify the chemical profile of a complex botanical mixture. GMP, process controls, stability programs and change-control strategies are essential. Pharmacovigilance is also complicated by incomplete product identification and herb–drug interactions. [36–43]

Table 1. Comparative regulatory overview

Figure 2. Qualitative author-created comparison of the presence of structured regulatory frameworks; it is not a quantitative ranking of jurisdictions.

Table 2. Regulatory challenges and recommended solutions

4. EMERGING REGULATORY PRIORITIES

Three themes are especially important for the next phase of herbal-medicine regulation: (i) stronger evidence generation, (ii) better quality and safety systems, and (iii) responsible use of technology. WHO's 2025–2034 strategy explicitly links traditional medicine regulation with research, innovation, sustainability, biodiversity and evidence-based integration. [1,2] Advanced analytical platforms may strengthen identity and consistency assessment, but they should complement not replace validated quality systems and clinically meaningful evidence.

5.IMPORTANCE OF REGULATORY CONTROL

Regulation protects patients from poor-quality products and provides a framework through which manufacturers can demonstrate reproducibility. A strong system addresses identity, purity, strength, quality, safety and efficacy as appropriate to the product category. It also creates mechanisms for inspections, laboratory testing, adverse-event reporting and market surveillance.

Table 1. Major regulatory objectives for herbal medicines.

6. BOTANICAL AUTHENTICATION AND IDENTIFICATION

Botanical authentication is the foundation of herbal quality. The scientific name, family, plant part and appropriate variety or chemotype should be established. Reliance on common names is unsafe because one common name may be applied to several species. Substitution can also occur when visually similar species are collected or when commercial materials are intentionally adulterated.

Authentication may use macroscopic examination, microscopic characters, organoleptic properties, taxonomic expertise, voucher specimens and chemical fingerprinting. DNA barcoding can be a useful complementary method for processed materials where morphology is difficult to assess. However, DNA authentication cannot establish the concentration of active or marker constituents, contaminant levels or therapeutic quality. Therefore, botanical identity should be integrated with chemical and physicochemical quality testing.

A practical regulatory system should require supplier qualification, documented source information and traceability. Each incoming batch should be linked to the supplier, collection or cultivation information and test results. Reference specimens or authenticated standards can support investigations when an unusual analytical result occurs.

7. RAW-MATERIAL VARIABILITY AND GACP

Natural variability is one of the defining challenges of herbal medicines. Plant chemistry can be influenced by genetics, soil nutrients, rainfall, temperature, altitude, light exposure, cultivation method, harvest timing and post-harvest treatment. Even material obtained from the same geographical area may vary from season to season.

Good Agricultural and Collection Practices reduce these risks by defining requirements for plant identification, propagation, cultivation or collection, harvesting, drying, primary processing, packaging, storage and transportation. GACP also supports traceability and helps ensure that raw material is collected from an appropriate source. [44]

For manufacturers, raw-material specifications should include botanical identity, plant part, physical characteristics, moisture or loss on drying where appropriate, foreign matter, microbial quality, relevant contaminants and chemical markers. Risk-based sampling should account for the heterogeneous nature of botanical material.

Failure to control raw materials can result in a finished product that meets some laboratory tests but does not have the same chemical or clinical characteristics as the material used during development. Therefore, GACP should be viewed as a pharmaceutical quality activity rather than merely an agricultural activity.

8. STANDARDIZATION AND BATCH-TO-BATCH CONSISTENCY

Standardization is a major scientific and regulatory challenge because a complex extract may contain multiple constituents contributing to activity. In many cases, the true active constituent is unknown. A single marker compound may therefore be insufficient to describe the overall quality of the extract.

A comprehensive control strategy may combine quantitative markers with chromatographic fingerprints, physicochemical characteristics and process controls. The objective is not necessarily to prove that every constituent is identical but to establish scientifically justified boundaries within which the product remains consistent with the material used to support safety and efficacy.

WHO guidance on marker substances recognizes the need for appropriate marker selection for quality control. [4] EMA's herbal quality guideline also provides herbal-specific expectations for quality aspects. [45] Modern chemometric and metabolomic approaches can assist in comparing batches, but these techniques require validated interpretation and appropriate reference materials.

Table 2. Approaches to standardization of herbal medicines.

9. CONTAMINATION, ADULTERATION AND SAFETY

Contamination may occur during cultivation, collection, drying, storage or manufacturing. Important hazards include microorganisms, pesticides, heavy metals or other elemental impurities, mycotoxins, foreign matter and residual solvents. The risk depends on the plant, geographical source, agricultural practices and manufacturing process.

Adulteration is a separate but serious problem. It may involve substitution with a cheaper plant, addition of undeclared pharmaceutical ingredients or dilution with unrelated materials. Adulteration can lead to therapeutic failure, unexpected toxicity and loss of confidence in herbal products.

A regulatory control program should therefore include supplier qualification, risk assessment, validated testing, appropriate acceptance criteria, traceability and investigation of out-of-specification results. WHO has specifically developed guidance addressing contaminants and residues in herbal medicines. [46]

The statement that 'natural means safe' is not a scientifically adequate basis for regulatory approval. Plants can contain toxic constituents and biologically active compounds. Safety can also be affected by dose, duration of use, patient characteristics, pregnancy, organ impairment and interactions with conventional medicines.

10. ANALYTICAL QUALITY CONTROL

Analytical characterization is essential for demonstrating identity, consistency and purity. Techniques are selected according to the plant material and dosage form. HPLC and HPTLC are commonly useful for non-volatile constituents; GC and GC-MS may be appropriate for volatile components and essential oils; LC-MS/MS can support sensitive analysis of specific constituents or contaminants; spectroscopic methods can provide rapid screening.

Analytical procedures must be fit for purpose. Where quantitative or qualitative claims are made, method performance should be demonstrated through appropriate validation. Specificity, accuracy, precision, range, robustness and other characteristics should be considered according to the intended use and relevant guidelines.

The complexity of herbal matrices can create matrix effects, co-eluting peaks and difficulties in obtaining reference standards. Therefore, analytical development should begin during product development rather than after clinical studies have been completed.

11. MANUFACTURING AND GMP

GMP provides the operational framework for reproducible manufacturing. WHO's GMP guidance for herbal medicines covers quality assurance, sanitation and hygiene, qualification and validation, complaints, recalls, personnel, premises, equipment, materials, documentation, production and quality control. [47]

For herbal products, GMP must be connected to raw-material control. Extraction yield, solvent-to-drug ratio, temperature, extraction time, concentration, drying and blending can influence the chemical profile. Process parameters should therefore be defined and controlled. Where applicable, process validation should demonstrate that the manufacturing process consistently produces material meeting established specifications.

Documentation is especially important. Batch manufacturing records, analytical results, deviations, change controls, cleaning records, supplier qualification and stability data should be maintained. A change in supplier, plant source or extraction process can alter the product and should be evaluated through formal change control.

12. STABILITY AND SHELF-LIFE

Stability is another difficult area because herbal preparations can undergo complex chemical changes. Oxidation, hydrolysis, volatilization, microbial growth, light exposure and moisture can change the quality profile. Different constituents may degrade at different rates.

Stability studies should evaluate relevant quality attributes under proposed storage conditions and support the assigned shelf-life. Packaging is part of the stability strategy because the container closure system may protect the product from moisture, oxygen and light. Stability-indicating analytical procedures should be selected where appropriate.

EMA's current herbal quality Q&A specifically covers stability together with specifications, testing, contaminants, manufacturing and water quality. [48] This illustrates that shelf-life should be supported by an integrated quality package rather than a single observation.

13. TOXICOLOGY AND HERB–DRUG INTERACTIONS

Safety evaluation should be based on the composition, dose, duration, route of administration, intended population and existing evidence. Products with extensive traditional use may have a different evidence pathway from novel botanical products, but the absence of reported toxicity is not proof of absolute safety.

Potential safety issues include hepatotoxicity, nephrotoxicity, cardiovascular effects, reproductive toxicity, genotoxicity and allergic reactions. Herb–drug interactions are also important, especially for patients taking medicines with narrow therapeutic ranges. Interactions may involve drug-metabolizing enzymes, transporters, pharmacodynamic effects or changes in absorption.

Identify constituents with known toxicological concern.

Assess exposure relative to traditional or proposed clinical use.

Evaluate interaction potential when clinically relevant.

Include warnings and contraindications supported by evidence.

Maintain post-marketing surveillance for rare events.

14. CLINICAL EFFICACY AND DEVELOPMENT CHALLENGES

Clinical development must establish whether the product provides the claimed benefit. The evidence required depends on the regulatory classification and jurisdiction. Traditional-use pathways may allow reliance on documented long-term medicinal use under defined conditions, whereas a novel botanical drug intended to treat a disease generally requires a conventional drug-development program.

One major problem is ensuring that the product used in clinical trials is representative of the commercial product. If the composition changes substantially between development and commercial manufacture, the clinical evidence may no longer adequately support the final product.

Randomized controlled trials of herbal products can face difficulties in creating matching placebos, controlling concomitant therapies and selecting appropriate endpoints. Standardized dose and formulation are essential. Safety monitoring should be systematic and should capture adverse events, laboratory abnormalities and possible interactions.

For traditional medicines, evidence should be documented rather than assumed. Traditional use can contribute to the evidence base, but regulatory authorities may still require proof of quality and appropriate safety.

15. UNITED STATES REGULATORY FRAMEWORK

In the United States, botanical products can fall into different regulatory categories depending on intended use and claims. FDA defines a botanical drug as a product intended for diagnosis, cure, mitigation, treatment or prevention of disease and notes that botanical drugs commonly have complex mixtures, lack a distinct active ingredient and may have substantial prior human use. [8,49]

FDA's Botanical Drug Development Guidance provides recommendations for IND and NDA development of botanical drugs. [50] The guidance recognizes that conventional approaches may require adjustment because of the unique features of botanical products. Nevertheless, quality, safety and efficacy remain central to development.

A developer should therefore establish early whether the intended product is a botanical drug or another category. Marketing claims are particularly important because a product positioned as a disease-treatment product may be subject to drug requirements.

16. EUROPEAN UNION REGULATORY FRAMEWORK

The European Union has a dedicated framework for herbal medicinal products and traditional herbal medicinal products. EMA's current effective quality guideline is Revision 3, which describes the special quality problems of herbal medicines and their differences from products containing chemically defined active substances. [45]

EMA's current Questions and Answers document, Revision 7, addresses declaration of active substances, specifications and testing, contaminants, manufacturing, water quality and stability. [48] This shows the breadth of the quality package expected for herbal medicines.

The European system also recognizes traditional herbal medicinal products. The European Commission notes that the HMPC establishes monographs and lists for certain traditional herbal substances, and applicants can use this information when registering eligible traditional products; quality still needs to be verified before approval. [51]

17. INDIAN REGULATORY PERSPECTIVE

India has a substantial traditional-medicine sector and a dedicated Ministry of AYUSH framework for Ayurveda, Siddha and Unani systems. Regulatory control includes licensing, quality standards, pharmacopoeial resources and GMP requirements. Developers must identify the applicable product category and authority before beginning development.

A further challenge is the interface between traditional medicines and modern phytopharmaceutical development. Products intended to be developed as scientifically standardized plant-derived drugs may require evidence and regulatory controls beyond those used for traditional preparations. Clear classification, quality characterization and appropriate clinical evidence are therefore essential.

For Indian manufacturers seeking international markets, compliance with Indian requirements may not be sufficient by itself. The target country may require additional evidence, different specifications, different labeling and a different application pathway.

18. INTERNATIONAL REGULATORY DIFFERENCES

International regulatory divergence increases development complexity. The same plant preparation can be treated as a medicine in one country, a traditional medicine in another and a supplement or complementary product elsewhere. These differences affect manufacturing standards, clinical evidence, permitted claims, labeling, licensing and post-market monitoring.

Table 3. Regulatory differences affecting international development.